Efficacy and safety of dapagliflozin in patients with CKD: real-world experience in 93 Italian renal clinics.

ABSTRACT:

Background

Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are recommended for reducing the renal and cardiovascular risk in patients with chronic kidney disease (CKD) based on the positive results reported by clinical trials. However, real-world data on the efficacy and the safety of these drugs in CKD population followed in nephrology setting are lacking.

Methods

We report the effects of dapagliflozin in CKD patients by using data collected during a learning program in which 105 nephrologists added dapagliflozin (10 mg/day) to consecutive patients referred to their renal clinics. Efficacy endpoints were the albuminuria change and the determinants of an albuminuria decline ≥30%. Adverse events were also collected.

Results

A total of 1724 patients with CKD (age 67

SUBMITTER: Minutolo R 

PROVIDER: S-EPMC11744308 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature